Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the effect of tolterodine ER in conjunction with behavioral intervention on
subject satisfaction in OAB subjects who were dissatisfied with their most recent
antimuscarinic OAB medication therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.